<?xml version='1.0' encoding='utf-8'?>
<document id="9864078"><sentence text="Gabapentin does not alter single-dose lithium pharmacokinetics."><entity charOffset="0-10" id="DDI-PubMed.9864078.s1.e0" text="Gabapentin" /><entity charOffset="38-45" id="DDI-PubMed.9864078.s1.e1" text="lithium" /><pair ddi="false" e1="DDI-PubMed.9864078.s1.e0" e2="DDI-PubMed.9864078.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9864078.s1.e0" e2="DDI-PubMed.9864078.s1.e1" /></sentence><sentence text="Lithium (Li) and gabapentin are both exclusively eliminated by renal excretion"><entity charOffset="0-7" id="DDI-PubMed.9864078.s2.e0" text="Lithium" /><entity charOffset="17-27" id="DDI-PubMed.9864078.s2.e1" text="gabapentin" /><pair ddi="false" e1="DDI-PubMed.9864078.s2.e0" e2="DDI-PubMed.9864078.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9864078.s2.e0" e2="DDI-PubMed.9864078.s2.e1" /></sentence><sentence text=" When used in combination, a competitive drug-drug interaction could possibly alter Li renal excretion with important clinical implications considering the rather narrow therapeutic index of Li" /><sentence text=" This study examined the single-dose pharmacokinetic profiles of Li in 13 patients receiving placebo and then steady-state gabapentin (mean daily dose: 3,646"><entity charOffset="123-133" id="DDI-PubMed.9864078.s4.e0" text="gabapentin" /></sentence><sentence text="15 mg)" /><sentence text=" During both phases, a single 600-mg dose of Li was orally administered with serial Li levels obtained at time zero and at 0" /><sentence text="25, 0" /><sentence text="5, 1, 2, 3, 4, 8, 12, 24, 48, and 72 hours" /><sentence text=" The pharmacokinetic parameters assessed were the following: area under the concentration time curve (AUC) for Li, maximal concentration of Li (Li Cmax), and time to reach peak Li concentration (Li Tmax)" /><sentence text=" For patients receiving gabapentin, the mean Li AUC at 72 hours was 9"><entity charOffset="24-34" id="DDI-PubMed.9864078.s10.e0" text="gabapentin" /></sentence><sentence text="91+/-3" /><sentence text="54 mmol x hr/mL and did not differ significantly from the mean Li AUC of 10" /><sentence text="19+/-2" /><sentence text="89 mmol x hr/mL for patients receiving placebo" /><sentence text=" The mean Li Cmax was 0" /><sentence text="69+/-0" /><sentence text="13 mmol/L for gabapentin patients and did not differ from the mean Li Cmax of 0"><entity charOffset="14-24" id="DDI-PubMed.9864078.s17.e0" text="gabapentin" /></sentence><sentence text="72+/-0" /><sentence text="15 mmol/L for placebo patients" /><sentence text=" The mean serum Li Tmax was 1" /><sentence text="38+/-0" /><sentence text="62 hours for gabapentin patients and did not differ significantly from the mean serum Li Tmax of 1"><entity charOffset="13-23" id="DDI-PubMed.9864078.s22.e0" text="gabapentin" /></sentence><sentence text="5+/-0" /><sentence text="91 hours for placebo patients" /><sentence text=" These data indicate that gabapentin treatment at this high therapeutic dose does not cause clinically significant alterations in short-term Li pharmacokinetics in patients with normal renal function"><entity charOffset="26-36" id="DDI-PubMed.9864078.s25.e0" text="gabapentin" /></sentence><sentence text=" These preliminary data warrant further controlled study in a larger, more heterogenous patient sample and a longer duration of assessment, but they do suggest that these two medications may be administered in combination for the management of bipolar disorder" /><sentence text="" /></document>